JFG
NPCE icon

Jefferies Financial Group’s Neuropace NPCE Stock Holding History

Jefferies Financial Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,900
Closed -$144K – 1740
2024
Q1 		$144K Buy
+10,900
New +$155K ﹤0.01% 1392

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's NPCE Position: Q2 2024 in Review

Jefferies Financial Group sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 10,900 shares — an estimated $144K sold.

Jefferies Financial Group first reported a position in NPCE in Q1 2024 and held it in 1 quarter. The position peaked at $144K in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

  • Jefferies Financial Group reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 10,900 Neuropace shares in Q2 2024, an estimated $144K.
  • Jefferies Financial Group first reported a position in Neuropace in Q1 2024 and held it in 1 quarter.
  • Jefferies Financial Group's Neuropace position peaked at $144K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Jefferies Financial Group's 13F filing for Q2 2024, filed 13 Aug 2024.